Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study

Prelude Therapeutics, Inc. ((PRLD)) announced an update on their ongoing clinical study.

Prelude Therapeutics, Inc. has launched a Phase 2 clinical study titled A Phase 2, Safety and Efficacy Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation. The study aims to evaluate the safety, tolerability, and efficacy of PRT3789 combined with pembrolizumab in patients with advanced solid tumors harboring a SMARCA4 mutation. This research is significant as it explores a novel treatment approach for a challenging cancer subtype.

The study tests the combination of PRT3789, a first-in-class SMARCA2 targeted protein degrader, and pembrolizumab, a monoclonal antibody targeting the PD-1 receptor. This combination is intended to enhance anti-tumor activity in patients with specific genetic mutations.

This interventional study is open-label and multi-center, with a sequential intervention model and no masking. The primary purpose is treatment, focusing on determining the optimal dose and assessing the overall response rate and duration of response.

The study commenced on June 3, 2025, with the latest update submitted on June 24, 2025. These dates are crucial as they mark the study’s progression and timeline for data collection and analysis.

The update may influence Prelude Therapeutics’ stock performance positively as it progresses in developing targeted cancer therapies. Investor sentiment could be bolstered by the collaboration with Merck Sharp & Dohme LLC, highlighting industry confidence in the study’s potential. Competitors in the oncology space will likely monitor these developments closely.

The study is currently recruiting, with further details available on the ClinicalTrials portal.